Claudia Soledad Sepúlveda

Dr. Claudia Soledad Sepúlveda

Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), CONICET- Universidad de Buenos Aires, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
CSClaudia Soledad Sepúlveda
Claudia Soledad Sepúlveda
CGCybele Carina García
Cybele Carina García
EDElsa Damonte
Elsa Damonte
Emerging and re-emerging viruses have been a challenge in public health in recent decades. Host-targeted antivirals (HTA) directed at cellular molecules or pathways involved in virus multiplication represent an interesting strategy to combat viruses presently lacking effective chemotherapy. HTA could provide a wide range of agents with inhibitory activity against current and future viruses that share similar host requirements and reduce the possible selection of antiviral-resistant variants. Nucleotide metabolism is one of the more exploited host metabolic pathways as a potential antiviral target for several human viruses. This review focuses on the antiviral properties of the inhibitors of pyrimidine and purine nucleotide biosynthesis, with an emphasis on the rate-limiting enzymes dihydroorotate dehydrogenase (DHODH) and inosine monophosphate dehydrogenase (IMPDH) for which there are old and new drugs active against a broad spectrum of pathogenic viruses.

13 September 2012 in Viruses
Verified
Journal Article
Open access
PDF file
FLFlorencia N. Linero
Florencia N. Linero
CSClaudia Soledad Sepúlveda
Claudia Soledad Sepúlveda
FGFederico Giovannoni
Federico Giovannoni
VCViviana Castilla
Viviana Castilla
CGCybele Carina García
Cybele Carina García
EDElsa Damonte
Elsa Damonte
Among the members of the Arenaviridae family, Lassa virus and Junin virus generate periodic annual outbreaks of severe human hemorrhagic fever (HF) in endemic areas of West Africa and Argentina, respectively. Given the human health threat that arenaviruses represent and the lack of a specific and safe chemotherapy, the search for effective antiviral compounds is a continuous demanding effort. Since diverse host cell pathways and enzymes are used by RNA viruses to fulfill their replicative cycle, the targeting of a host process has turned an attractive antiviral approach in the last years for many unrelated virus types. This strategy has the additional benefit to reduce the serious challenge for therapy of RNA viruses to escape from drug effects through selection of resistant variants triggered by their high mutation rate. This article focuses on novel strategies to identify inhibitors for arenavirus therapy, analyzing the potential for antiviral developments of diverse host factors essential for virus infection.

9 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JBJimena Borgo
Jimena Borgo
MWMariel Wagner
Mariel Wagner
LLLaura Cecilia Laurella
Laura Cecilia Laurella
OEOrlando Elso
Orlando Elso
MSMariana G. Selener
Mariana G. Selener
Valeria P. SülsenValeria P. Sülsen
Valeria P. Sülsen
Asteraceae (Compositae), commonly known as the sunflower family, is one of the largest plant families in the world and includes several species with pharmacological properties. In the search for new antiviral candidates, an in vitro screening against dengue virus (DENV) was performed on a series of dichloromethane and methanolic extracts prepared from six Asteraceae species, including Acmella bellidioides, Campuloclinium macrocephalum, Grindelia pulchella, Grindelia chiloensis, Helenium radiatum, and Viguiera tuberosa, along with pure phytochemicals isolated from Asteraceae: mikanolide (1), eupatoriopicrin (2), eupahakonenin B (3), minimolide (4), estafietin (5), 2-oxo-8-deoxyligustrin (6), santhemoidin C (7), euparin (8), jaceidin (9), nepetin (10), jaceosidin (11), eryodictiol (12), eupatorin (13), and 5-demethylsinensetin (14). Results showed that the dichloromethane extracts of C. macrocephalum and H. radiatum and the methanolic extracts prepared from C. macrocephalum and G. pulchella were highly active and selective against DENV-2, affording EC50 values of 0.11, 0.15, 1.80, and 3.85 µg/mL, respectively, and SIs of 171.0, 18.8, >17.36, and 64.9, respectively. From the pool of phytochemicals tested, compounds 6, 7, and 8 stand out as the most active (EC50 = 3.7, 3.1, and 6.8 µM, respectively; SI = 5.9, 6.7, and >73.4, respectively). These results demonstrate that Asteraceae species and their chemical constituents represent valuable sources of new antiviral molecules.

12 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SMSofía Maldonado
Sofía Maldonado
PFPedro Fuentes
Pedro Fuentes
EBEzequiel Bernabeu
Ezequiel Bernabeu
FBFacundo Bertera
Facundo Bertera
JOJavier Opezzo
Javier Opezzo
DCDiego A. Chiappetta
Diego A. Chiappetta
Background/Objective: World Health Organization latest statistics state that 17% of infectious diseases are transmitted by vectors, causing more than 700,000 deaths each year. Particularly, dengue (DENV), Zika (ZIKV) and yellow fever (YFV) viral infections have generated international awareness due to their epidemic proportion and risks of international spread. In this framework, the repositioning strategy of Efavirenz (EFV) represents a key clinical feature to improve different antiviral therapies. Therefore, the development of Soluplus®-based nanomicelles (NMs) loaded with EFV (10 mg/mL) for optimized oral pharmacotherapy against ZIKV, DENV and YFV infections was investigated. Methods: EFV-NMs were obtained by an acetone diffusion technique. Micellar size and in vitro micellar interaction with mucin were assessed by dynamic light scattering. In vitro cytocompatibility was investigated in A549 and Vero cells and micellar in vitro antiviral activity against ZIKV, DENV and YFV was evaluated. In vivo oral bioavailability and histological studies were assessed in Wistar rats. Results: EFV encapsulation within Soluplus® NMs increased the drug’s apparent aqueous solubility up to 4803-fold with a unimodal micellar size distribution and a micellar size of ~90 nm at 25 and 37 °C. Micellar in vitro interaction with mucin was also assessed in a pH range of 1.2–7.5 and its storage micellar physicochemical stability at 4 °C was confirmed over 2 years. In vitro cytocompatibility assays in A549 and Vero cells confirmed that EFV micellar dispersions resulted in safe nanoformulations. Interestingly, EFV-loaded NMs exhibited significantly higher in vitro antiviral activity compared with EFV solution for all the tested flaviviruses. In addition, the selectivity index (SI) values reveal that EFV-loaded NMs exhibited considerably more biological efficacy compared to EFV solution in A549 and Vero cell lines and for each viral infection (SI > 10). Further, the drug pharmacokinetics parameters were enhanced after the oral administration of EFV-loaded NMs, being biocompatible by not causing damage in the gastrointestinal segments. Conclusions: Overall, our EFV nanoformulation highlighted its potential as a novel drug delivery platform for optimized ZIKV, DENV and YFV antiviral therapy.

1 February 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Victoria Belen Ayala-PeñaVictoria Belen Ayala-Peña
Victoria Belen Ayala-Peña
AJAna Karen Jaimes
Ana Karen Jaimes
ACAna Lucía Conesa
Ana Lucía Conesa
CGCybele Carina García
Cybele Carina García
CSClaudia Soledad Sepúlveda
Claudia Soledad Sepúlveda
VLVerónica Leticia Lassalle
Verónica Leticia Lassalle
Viral infections remain a major concern, as existing treatments often yield inadequate responses or lead to the development of antiviral resistance in some cases. Fucoidan extracted from Undaria pinnatifida (F) is a natural sulphated polysaccharide that exhibits antiviral action. Despite its potential, the biomedical application of F is limited due to its difficult administration through trans-mucosal, skin, or oral ingestion. The most effective way to solve these problems is to propose novel methods of administration aiming to ensure better contact between the biopolymers and pathogens, leading to their inactivation. In this work, the synthesis of films based on chitosan (Ch)-coupled F is reported, aiming to generate a synergic effect between both biopolymers in terms of their antiviral and antioxidant capability. Biocomposites were prepared by a sonochemical method. They were characterized to infer structural properties, functionality, and possible F-Ch interactions by using Zeta potential, FTIR, and XRD techniques. The biocomposites showed excellent film-forming ability. They also exhibited improved antioxidant activity with respect to F and Ch individually and proved to be non-cytotoxic. These results demonstrate, for the first time, the antiviral activity of F:Ch biocomposites against bovine coronavirus and human viruses (adenovirus, poliovirus, herpes simplex, and respiratory syncytial virus), which could be applied in film form to prevent or treat viral infections.

21 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
MCMayra A. Castañeda Cataña
Mayra A. Castañeda Cataña
AMAndrea P. Rivas Marquina
Andrea P. Rivas Marquina
MTMartín M. Dodes Traian
Martín M. Dodes Traian
MCMaria Carlucci
Maria Carlucci
EDElsa Damonte
Elsa Damonte
CSClaudia Soledad Sepúlveda
Claudia Soledad Sepúlveda
The global spread of viral diseases is a public health issue. Ribavirin (RBV) and mycophenolic acid (MPA) are well-known wide-spectrum antiviral agents. The present study evaluated the potential of bovine serum albumin (BSA) nanoparticles (NPs) as a vehicle to improve the efficacy of molecules with antiviral activity. The results demonstrated that NPs offer a promising strategy for the delivery of antiviral drugs, improving their stability and reducing toxicity compared to free agents. BSA-based NPs effectively encapsulated hydrophilic molecules such as MPA and water-soluble compounds such as RBV, achieving encapsulation efficiencies of 10% and 20%, respectively. The purified NPs exhibited a particle size between 60 and 100 nm and did not show toxicity at the evaluated concentrations. In cellular viral infection models against Zika virus (ZIKV), Junín virus (JUNV), vesicular stomatitis virus (VSV) and herpes simplex virus (HSV-1), the BSA-based NPs loaded with MPA or RBV demonstrated antiviral properties superior to those of non-encapsulated agents, as well as 100- and 200-fold effective dose reductions, respectively. These findings clearly indicate the potential of BSA NPs as a novel platform for the development of safer and more efficient antiviral therapies.